Literature DB >> 15080861

Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.

K Pulkkinen1, M Luomala, H Kuusisto, T Lehtimäki, M Saarela, T O Jalonen, I Elovaara.   

Abstract

Chemokines and their receptors participate in the development of multiple sclerosis (MS) by guiding immune cells into the brain tissue. A CCR5 Delta32 deletion mutation abolishes functional CCR5 on the cell surface and may reduce cell entry into the lesion sites. To analyse the significance of this mutation in MS, we compared the frequencies of CCR5 genotype in peripheral blood mononuclear cells from 89 MS patients and 119 healthy controls. The CCR5 genotype was further compared with the CCR5 RNA and surface protein expression in 48 MS patients and their controls. In all MS patients, the Delta32/32 genotype was found with 6.7% frequency, whereas it was present only in 0.8% of the controls (6/89 vs 1/119, P = 0.01). Specifically, the Delta32/Delta32 genotype was increased (11.5%, P = 0.05) among primary progressive MS patients, whereas it was present only in 4.8% in other MS subtypes and only in 0.8% of the controls. The amount of CCR5 protein on CD4(+) cells analysed in 48 MS patients (nine primary progressive MS, 18 secondary progressive MS, 21 relapsing-remitting MS) and 13 controls decreased with genotype, being 8.9% in wt/wt, 7.7% in wt/Delta32 and 4.3% in Delta32/Delta32. CCR5 surface expression analysed on these 48 MS patients and 13 controls was significantly decreased in Delta32/Delta32 MS patients as compared with that in wt/wt genotype individuals (P = 0.004). The significantly increased number of Delta32/Delta32 individuals among our MS patients suggests that this genotype could contribute as a general risk factor for MS. However, neither the levels of RNA or surface protein correlated with MS subtype, neurological disability as expressed by expanded disability status scale, or disease progression index. Our results suggest that the lack of CCR5 does not protect from MS, but rather it may predispose to the chronic course of the disease. This would further imply that in view of the redundancy in the chemokine system, CCR5 ligands must be assumed to function through other closely related chemokine receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080861     DOI: 10.1046/j.1600-0404.2003.00233.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  10 in total

1.  CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients.

Authors:  Thiago Hissnauer Leal Baltus; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Helena Kaminami Morimoto; Francieli Delongui; Daniela Frizon Alfieri; Tatiane Mayumi Veiga Iriyoda; Isaias Dichi; Andrea Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Rheumatol Int       Date:  2015-06-14       Impact factor: 2.631

Review 2.  Is the CCR5 Δ 32 mutation associated with immune system-related diseases?

Authors:  Khodayar Ghorban; Maryam Dadmanesh; Gholamhossein Hassanshahi; Mohammad Momeni; Mohammad Zare-Bidaki; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

3.  CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population.

Authors:  Majid Shahbazi; Hamid Ebadi; Davood Fathi; Danial Roshandel; Mana Mahamadhoseeni; Azam Rashidbaghan; Narges Mahammadi; Mahammad Reza Mahammadi; Mahdi Zamani
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

4.  Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.

Authors:  A P Kallaur; S R Oliveira; A N C Simão; E R D de Almeida; H K Morimoto; J Lopes; L M Pelegrino; W L C J de Pereira; Daniele Frizon Alfieri; R M Andrade; S D Borelli; M A E Watanabe; D R Kaimen-Maciel; E M V Reiche
Journal:  J Mol Neurosci       Date:  2014-04-04       Impact factor: 3.444

5.  Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis.

Authors:  D Otaegui; J Ruíz-Martínez; J Olaskoaga; J I Emparanza; A López de Munain
Journal:  Neurogenetics       Date:  2007-03-10       Impact factor: 3.017

6.  Association of interleukin-4 polymorphisms with multiple sclerosis in southeastern Iranian patients.

Authors:  Mohammad Kazemi Arababadi; Reza Mosavi; Ali Ravari; Hossein Teimori; Gholamhossein Hassanshahi
Journal:  Ann Saudi Med       Date:  2012 Mar-Apr       Impact factor: 1.526

7.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30

8.  Could FIV zoonosis responsible of the breakdown of the pathocenosis which has reduced the European CCR5-Delta32 allele frequencies?

Authors:  Eric Faure
Journal:  Virol J       Date:  2008-10-16       Impact factor: 4.099

9.  Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.

Authors:  Sana Eltayeb; Anna-Lena Berg; Hans Lassmann; Erik Wallström; Maria Nilsson; Tomas Olsson; Anders Ericsson-Dahlstrand; Dan Sunnemark
Journal:  J Neuroinflammation       Date:  2007-05-07       Impact factor: 8.322

Review 10.  Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.

Authors:  Anandi Rautenbach; Aurelia A Williams
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.